We know that Abiraterone (Zytiga) extends life, but we also know that its side effects can be harsh, especially in elderly men (men over 75 years). We also know that men with metastatic, castrate resistant prostate cancer (mCRPC) have a limited potential life expectancy. Given these facts, it is important to know if, despite being [...]
Because of the large amount of prostate cancer screening there has been a major shift in initial staging in prostate cancer in western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%. Despite this very significant drop in late stage diagnoses prostate cancer is [...]
There have been some randomized studies that have shown that when prednisone is used in combination with docetaxel (chemotherapy) there is an improved survival in men who have metastatic castration-resistant prostate cancer (mCRPC). To add to our understanding of the possible clinical value of this combination of drugs some researchers have retrospectively evaluated whether the [...]
In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy) enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]
Are you stressed? If you are and you have been treated for clinically localized prostate cancer you are at a 66% increased risk of dying from your prostate cancer! Research has shown that high stress levels are associated with an increased rate of prostate cancer (PCa) specific mortality among men treated for clinically localized prostate [...]